methyl 2-tetradecylglycidate has been researched along with etomoxir in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arduini, A; Ceccarelli, SM; Chomienne, O; Gubler, M | 1 |
| Friedman, MI; Horn, CC; Ji, H | 1 |
2 other study(ies) available for methyl 2-tetradecylglycidate and etomoxir
| Article | Year |
|---|---|
Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective on 35 years of research.
Topics: Animals; Carnitine; Carnitine O-Palmitoyltransferase; Catalytic Domain; Diabetes Mellitus, Type 2; Energy Metabolism; Enzyme Activators; Ethylene Oxide; Heart Failure; Humans; Insulin Resistance; Isoenzymes; Lipid Metabolism; Myocardial Ischemia; Organ Specificity; Protein Conformation; Sequence Homology, Amino Acid; Stereoisomerism | 2011 |
Etomoxir, a fatty acid oxidation inhibitor, increases food intake and reduces hepatic energy status in rats.
Topics: Adenosine Diphosphate; Adenosine Triphosphate; Animals; Eating; Energy Metabolism; Enzyme Inhibitors; Epoxy Compounds; Liver; Male; Mannitol; Oxidation-Reduction; Propionates; Rats; Rats, Sprague-Dawley | 2004 |